Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.52 |
| ▸ | PGR | P06401 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524698 | 1.00 | NR3C1 (1.00) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28616207 | 0.84 | NR3C1 (0.72) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4515569 | 0.81 | NR3C1 (0.68) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17847425 | 0.77 | L3MBTL1 (1.00) | NR3C1ALDH1A1L3MBTL1POLB | |
| SCHEMBL4514417 | 0.76 | NR3C1 (0.62) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12462411 | 0.76 | ALDH1A1 (0.71) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12462450 | 0.76 | ALDH1A1 (0.71) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15218455 | 0.76 | ALDH1A1 (0.71) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3229627 | 0.74 | NR3C1 (0.65) | NR3C1L3MBTL1NR3C2PGR | |
| SCHEMBL13889012 | 0.74 | ALDH1A1 (0.83) | NR3C1ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| EP-1807391-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046916-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885ALDH1A1 2398/4885CYP1A2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.